ReviewJournal of orthopaedic surgery and research2025
Co-morbid mechanisms of intervertebral disc degeneration and osteoporosis: biomechanical coupling and molecular pathways synergistically driving degenerative lesions.
Review in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- Gut-Intervertebral Disc Axis: Gut Microbiome-Driven Immune-Metabolic Imbalance and Intervertebral Disc Degeneration.Journal of cellular physiology · 2026Review
- A Novel SIRT1 Activator Hydroxygenkwanin Alleviates Osteoporosis by Inhibiting Ferroptosis and Lactylation in Skeletal Stem/Progenitor Cells.Antioxidants (Basel, Switzerland) · 2026Article
- Research on zoledronic acid's synergistic improvement of intervertebral disc degeneration and osteoporosis by regulating inflammation matrix microenvironment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Plastrum Testudinis Extract Ameliorates Intervertebral Disc Degeneration by Suppressing NF-κB Mediated Senescence and Inflammation.Journal of immunology research · 2026Article
- The Biomechanical Landscape of Lumbar Disc Herniation: Mechanobiological Insights Into Injury and Regeneration.Neurospine · 2026Review
- Senescence-associated secretory phenotype: the "pathogenic" factor driving orthopedic degenerative diseases and its regulation.Frontiers in aging · 2026Review
- Nystose treats intervertebral disc degeneration via the Nrf2 axis: a focus on oxidative stress and ferroptosis.Frontiers in pharmacology · 2026Article
- Analysis of influencing factors and predictive performance of lumbar disc herniation in elderly patients with osteoporosis.Frontiers in endocrinology · 2026Article
- Context-dependent roles of the NLRP3 inflammasome in osteomyelitis and strategies for precision modulation.Frontiers in immunology · 2026Review
- Deciphering the regulatory mechanism and therapeutic potential of ECM degradation in intervertebral disc degeneration via multi-omics integration.Frontiers in immunology · 2026Article
- Biomaterials targeting senescent cells for bone regeneration: State-of-the-art and future perspectives.Bioactive materials · 2025Review
- Recent advances in targeting the cGAS-STING pathway for immunotherapy in orthopedic diseases.Frontiers in immunology · 2025Review
- Mechanism-guided biomaterial strategies for intervertebral disc degeneration: Pathological heterogeneity, functional classification, and translational perspectives.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Degenerative orthopedic illnesses, such as osteoporosis (OP) and intervertebral disc degeneration (IVDD), are common in the elderly and are defined by loss of bone mass and degradation of the intervertebral disc matrix, respectively. These conditions cause persistent pain and disability. Although more research has been done on the two diseases' distinct causes, epidemiology indicates that their co-morbidity incidence has dramatically grown, pointing to a synergistic pathogenic network. Big data-driven dual-disease research offers a fresh approach to exposing the pathophysiology of co-morbidities, as the conventional single-disease research model makes it challenging to examine the interaction mechanisms. Research has indicated that the co-morbidities are primarily caused by metabolic and biomechanical disorders: A vicious cycle of "mechanics-bone loss" is created when deteriorated discs hasten the breakdown of the bone microarchitecture through spinal instability, while OP-induced reductions in bone mineral density (BMD) cause aberrant loading of the intervertebral discs. At the molecular level, inflammatory factors like TNF-α and IL-1β contribute to the "inflammation-degeneration-bone loss" axis by activating the NF-κB pathway, which in turn promotes osteoclast activation (RANKL/OPG imbalance) and intervertebral disc matrix breakdown (upregulation of matrix metalloproteinases (MMPs)). Convergence of senescence signaling makes the co-morbid process worse: SASP/ROS-induced apoptosis in bone tissue and p53/p21-mediated senescence in disc nucleus pulposus cells work together to alter microenvironmental homeostasis through SASP secretion simultaneously. Autophagy and epigenetic modification are both modulated via the SIRT1/mTOR pathway, while autophagy and epigenetic modification are regulated by exosomal miRNAs (e.g., miR-31, miR-143-5p). 143-5p) mediate the signaling of trans-tissue senescence. Oxidative stress and chronic inflammation are amplified by immunometabolic reprogramming (macrophage M1 polarization, NLRP3 inflammatory vesicle activation) and anomalies in mitochondrial energy metabolism (reduced ATP generation). To study the mechanisms of bone-disc mechanotransduction and molecular dialogue, create multi-targeted synergistic intervention strategies, and screen bi-directional regulatory biomarkers, we must combine biomechanical modeling and single-cell multi-omics technology in the future. This will provide theoretical advances for the development of an accurate therapeutic system that considers tissue homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.